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Indirubin derivatives gained interest in recent years for their anticancer and antimetastatic properties.
The objective of the present study was to evaluate and compare the anticancer properties of the two
novel bromo-substituted derivatives 6-bromoindirubin-30-oxime (6BIO) and 7-bromoindirubin-30-oxime
(7BIO) in five different breast cancer cell lines. Cell viability assays identified that 6BIO and 7BIO are most
effective in preventing the proliferation of the MDA-MB-231-TXSA breast cancer cell line from a total of
five breast cancer cell lined examined. In addition it was found that the two compounds induce apoptosis
via different mechanisms. 6BIO induces caspase-dependent programmed cell death through the intrinsic
(mitochondrial) caspase-9 pathway. 7BIO up-regulates p21 and promotes G2/M cell cycle arrest which is
subsequently followed by the activation of two different apoptotic pathways: (a) a pathway that involves
the upregulation of DR4/DR5 and activation of caspase-8 and (b) a caspase independent pathway. In con-
clusion, this study provides important insights regarding the molecular pathways leading to cell cycle
arrest and apoptosis by two indirubin derivatives that can find clinical applications in targeted cancer
therapeutics.
 2012 Elsevier Inc. All rights reserved.1. Introduction
Indirubin is a bisindole alkaloid of red/purple color and is an
isomer of the blue color indigo. Indirubins can be extracted from
about 200 indigo dye-producing species. They are also present in
about 15 species of Muricidae mollusks [1] and in some bacteria
[2,3]. In addition, these compounds have been detected in human
urine [4]. Indirubin is considered to be the active ingredient of
the Danggui Longhui Wan, an extract that was used for the treat-
ment of chronic myelocytic leukemia in traditional Chinese medi-
cine [5]. Indirubins’ low solubility in water and their poorll rights reserved.
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nou).bioavailability [6] lead to the synthesis of a series of derivatives
with improved qualities, some of which turned out to be potent
glycogen synthase kinase-3b (GSK-3b) inhibitors [1,7]. Further-
more, several of these synthetic derivatives have been shown to
act as potent CDK1 and CDK5 inhibitors by competing with ATP
for binding to the catalytic site of the kinase [8].
Much of the recent literature on indirubins has been concen-
trating on 6-bromoindirubin-30-oxime (6BIO) and 7-bromoindiru-
bin-30-oxime (7BIO), two indirubin derivatives that differ only in
the position of the bromine on their aromatic ring (Fig. 1).
Although both 6BIO and 7BIO had been reported to induce rapid
cell death in different tumor cell lines, the death mechanisms are
not fully understood and there are conflicting reports in the litera-
ture as to the exact pathways activated by each agent. 6BIO, a
strong inhibitor of GSK-3b (IC50 = 0.005 lM), CDK1 (IC50 =
0.320 lM), and CDK5 (IC50 = 0.083 lM), has been shown to induce
apoptosis in various cancer cell lines including colon (HT-29,
HCT116), breast (MDA-MB-231), lung (A549), prostate (PC3), hep-
atoma (5L, BP8, F1, Huh7) and neuroblastoma (SH-SY5Y) [1,9,10].











Fig. 1. Chemical structure of 6-bromoindirubin-30-oxime (6BIO) and 7-bromoin-
dirubin-30-oxime (7BIO).
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(IC50 = 33 lM) [8], has been reported to cause non apoptotic or a
special type of necrotic cell death in neuroblastoma (SH-SY5Y),
leukemia (Jurkat) and breast (MDA-MB-231) cancer cell lines
[8,11]. From these results it is becoming apparent that the ability
of the two derivatives to kill cancer cells is independent of their
ability to inhibit GSK-3b and CDKs and the mode of death may
be also dependent on cell content.
The objectives of the present study were to: (a) identify breast
cancer cells that are especially susceptible to 6BIO and 7BIO, and
(b) to thoroughly elucidate the programmed cell death pathways
engaged by each compound in the selected cell line. Our results
show that although both compounds effectively retard the growth
of breast cancer cell lines, 6BIO clearly induces a caspase-9 depen-
dent apoptotic pathway, whereas 7BIO produces the induction of a
G2/M phase cell cycle arrest and the activation of both a caspase-8
dependent and a caspase independent pathway of apoptosis.2. Materials and methods
2.1. Synthesis of 6BIO and 7BIO
The derivatives 6BIO and 7BIO were prepared by Dr. Skaltsounis
laboratory as previously described [9,10].2.2. Cell lines
The MDA-MB-231 derivative cell line MDA-MB-231-TXSA was
kindly provided by Dr. Andreas Evdokiou (Royal Adelaide Hospital,
University of Adelaide, Australia). These cells have been selected
for their increased propensity to metastasize to the bone [12]. Cells
were cultured in DMEM purchased from Invitrogen (Carlsbad, CA),
supplemented with 2 mM glutamine, 100 IU/ml penicillin,
100 lg/ml streptomycin, 160 lg/ml gentamicin and 10% fetal
bovine serum from Invitrogen (Carlsbad, CA) and maintained in a
5% CO2 atmosphere.2.3. Measurement of cell viability
Cells (1  105) were seeded in 96-well microtiter plates and
24 h latter treated with 6BIO or 7BIO as indicated. Cell viability
was assessed after 24 h or 48 h using the CellTiter-Blue assay from
Promega (Madison, MI) which measures the indicator dye resazu-
rin at 570 nm wavelength to evaluate the metabolic capacity of
cells. The Crystal Violet staining assay was also used by measure-
ment of absorbance at 570 nm wavelength [13]. Unless otherwise
indicated, in all subsequent experiments 6BIO and 7BIO were used
at a final concentration of 15 lM.2.4. Measurement of DEVD-caspase activity
A total of 1  105 cells per well were seeded in 6-well microtiter
plates and allowed to adhere for 24 h. Cells were then treated with
6BIO or 7BIO as indicated for several time points (0–48 h). Mea-
surement of caspase-3 activity was done as described before
[13,14].
2.5. Western blot analysis
Cells were treated as indicated for 0–48 h, lysed and analyzed as
previously described [13]. Anti-caspase-8, anti-caspase-9 and Bax
antibodies were purchased from Cell Signaling Technology (Dan-
vers, MA), anti-caspase-3 and anti-FADD antibodies from Trans-
duction Laboratories and anti-poly ADP ribose polymerase (PARP)
antibodies from Roche Diagnostics (Indianapolis, IN). Anti-p21
antibody was purchased from Santa-Cruz biotechnology (Heidel-
berg, Germany) and anti-p53 antibody from ZYMED laboratories
(San Francisco, CA). TRAIL receptors (DR4, DR5) were purchased
from R&D systems (Minneapolis, MN). Anti-actin monoclonal anti-
body from Sigma (St. Louis, MO) was used as a loading control.
2.6. DAPI staining
Circular TC-treated cover slips were placed at the bottom of
each well of a 24-well plate. A total of 1  105 of MDA-MB-231-
TXSA cells were seeded in each well and incubated for 24 h.
Growth medium was removed, replaced with fresh DMEM or
DMEM supplemented with 15 lM of 6BIO or 7BIO. After 24 h, the
medium was removed and the cells were incubated for 10 min
with 1 lg/ml DAPI stain purchased from Roche Diagnostics (India-
napolis, IN). The morphology of the cell nuclei was observed using
a fluorescence microscope (Olympus BH Series) at excitation wave-
length 350 nm.
2.7. Cell death detection ELISA
A total of 1  105 MDA-MB-231-TXSA cells per well were
seeded in 96-well microtiter plates and allowed to adhere for
24 h. Cells were treated with the indirubin derivatives as indicated,
and lysed after 24 and 48 h respectively. Lysates (for apoptosis)
and supernatant (for necrosis) were analyzed for the presence of
nucleosomes using the Cell Death Detection ELISA Plus kit pur-
chased from Roche, Diagnostics (Indianapolis, IN). Absorbance
was measured at 405 nm.
2.8. TaliTM Apoptosis Kit
Cells were plated in 60-mm plates and treated with 6BIO and
7BIO. After 24 h and 48 h of treatment, cells were harvested and
stained using annexin-V Alexa Fluor 488/PI staining, as described
by the TaliTM apoptosis kit from Invitrogen, (Carlsbad, CA). As a po-
sitive control we used etoposide (100 lg/ml). Cell viability, death
and apoptosis were evaluated using the TaliTM Image-based
Cytometer.
2.9. Cell cycle analysis
MDA-MB-231-TXSA cells (3  106) were incubated in complete
growth medium in the presence or absence of 15 lM 7BIO or 6BIO
for several time points. The cells were collected by centrifugation
and fixed with 70% cold ethanol for 2 h on ice. Cells were then incu-
bated with the Propidium Iodide (PI) staining solution (containing
10 lg/ml PI and 0.2 mg/ml RNase A) for 45 min at 37 C. Cells were
then analyzed by a Becton Dickinson FACS Calibur flow cytometer.
Table 1
IC50 values of breast cancer cell lines treated with 6BIO or 7BIO. Values are expressed
in lM and were calculated from corresponding data presented in Fig. 2. The data are
expressed as the mean (±SE) of the results from three separate experiments.
Cell line Treatment
6BIO 7BIO
MCF-7 21.2 (±5.7) 20.0 (±3.1)
ZR75 22.3 (±2.5) 16.7 (±2.9)
MDA-MB-231 17.0 (±3.6) 17.4 (±4.2)
MDA-MB-468 17.4 (±3.3) 6.6 (±1.0)
MDA-MB-231-TXSA 9.2 (±3.5) 2.3 (±4.6)
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G2/M) were calculated using CellQuest 3.3 software.
2.10. Statistical analysis
Experiments were done in triplicates and repeated at least two
times. Values are presented as the mean ± SEM. Statistical signifi-
cance was evaluated using Student’s two-tailed t-test. P < 0.05
was considered statistically significant.
3. Results and discussion
3.1. Anti-proliferative effects of 6-BIO and 7-BIO
To compare the two indirubin derivatives (6BIO and 7BIO) for
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Fig. 2. Effect of 6-BIO and 7-BIO on the survival of (A) MCF-7, (B) ZR75, (C) MDA-MB-231
increasing concentrations of 6BIO and 7BIO. Cell survival was estimated with the CellTi
cells. Average ± S.E. of at least three independent experiments with three independent mbreast cancer cell lines, we determined cell viability at 24 and
48 h after treatment with selected doses (0–50 lM) of the two der-



























































, (D) MDA-MB-468 and (E) MDA-MB-231-TXSA cells. Cells were exposed for 48 h to
ter-Blue cell viability assay and is expressed in percentage of survival in untreated
easurements per experiment.
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the two derivatives is shown in Fig. 2. 6BIO and 7BIO reduced cell
viability in a dose-dependent manner (Fig. 2A–E). The effect of
7BIO was almost identical to the effect of 6BIO in MCF-7 and
MDA-MB-231 cells (Fig. 2A and C) whereas for the other three cell
lines 7BIO was a stronger inhibitor (Fig. 2B, D and E). This is also
reflected in the IC50 values presented in Table 1. MDA-MB-231-
TXSA was the most sensitive of all cell lines examined with IC50
values of 9.2 lM (±3.56) for 6BIO and 2.3 lM (±4.63) for 7BIO (Ta-
ble 1). Since the highly metastatic MDA-MB-231-TXSA breast can-
cer cells were the most sensitive to both agents the mechanism of































































Fig. 3. Effect of 6-BIO (15 lM) and 7-BIO (15 lM) on apoptosis and caspase-3 activity in
24 h and 48 h as shown and analyzed for the presence of nucleosomes using the Cell
Annexin-V Alexa FluorR 488/PI staining. Cells were plated in 60-mm plates and treated w
with the TaliTM Image-based Cytometer using the TaliTM apoptosis kit. As a positive cont
were treated for (0–48 h) with 6BIO or 7BIO and caspase-3 activity was evaluated using th
Methods. (D) Tumor cells were treated with several concentrations of 6BIO or 7BIO for
presence or absence of 50 lM Z-VAD (OMe)-FMK, (p values: 6BIO vs. 6BIO + Z-VAD < 0.01
24 h and morphology of the cell nuclei were observed after DAPI staining using a fluore3.2. Induction of apoptosis by 6-BIO and 7-BIO
The effects of the two indirubin derivatives on cell death were
initially evaluated by a cell death ELISA assay which detects cyto-
plasmic histone-associated DNA-fragments produced after cell
death. Both 6BIO and 7BIO increased apoptosis significantly at
24 h of treatment while no further increase was evident after
48 h of treatment (Fig. 3A). Apoptotic induction was also analyzed
using the TaliTM Apoptosis Kit, where Annexin V and Propidium Io-
dide (PI) are used for determination of apoptotic cell death. Treat-
ment with 6BIO and 7BIO for 24 h resulted in about 38% and 42% of














































































the MDA-231-TXSA tumor cells. (A) Tumor cells were treated with 6BIO or 7BIO for
Death Detection ELISA. (B) Effect of 6BIO and 7BIO on tumor cell apoptosis using
ith either one of the test agents for 24 h. Cell viability and apoptosis were evaluated
rol we used cells treated with 100 lg/ml etoposide. (C) Cells were left untreated or
e caspase-3 specific fluorogenic substrate, zDEVD-AFC, as described in Material and
48 h and cell viability was evaluated with CellTiter-Blue cell viability assay, in the
**, 7BIO vs. 7BIO + Z-VAD < 0.05*). (E) Tumor cells were treated with 6BIO or 7BIO for
scence microscope.
80 K.A. Nicolaou et al. / Biochemical and Biophysical Research Communications 425 (2012) 76–82apoptotic) (Fig. 3B). Treatment with etoposide (100 lg/ml), which
was used as a positive control, resulted in 51% Annexin V positive
cells.
To determine if apoptosis was associated with caspase-3 activa-
tion we treated MDA-MB-231-TXSA cells with various concentra-
tions of the two indirubin derivatives for 24 h and measured its
activity (data not shown). In a time response curve a small increase
in caspase-3 activity was evident after 48 h of treatment with 7BIO
(Fig. 3C). However, the effect of 6BIO, which became evident at ear-
lier times, was much stronger at 48 h compared to that of 7BIO. In
particular, 6BIO induced a 6-fold increase in caspase-3 activity
(Fig. 3C). Consistent with this finding, the general caspase inhibitor
Z-VAD (OMe)-FMK, increased the viability of the cells that had been
treated with 6BIO to almost the control value while a smaller effect
was evident in 7BIO/Z-VAD (OMe)-FMK -treated cells (Fig. 3D).
These findings show that although both compounds induce apopto-













































Fig. 4. Effects of 6-BIO and 7-BIO on key proteins participating in apoptosis and cell cyc
15 lM 7BIO for the times indicated. Cells were then harvested and protein extracts w
immunoblotting results of (C) 6BIO treatment and (D) 7BIO treatment was performed usi
independent experiments with three independent measurements per experiment.caspase mediated pathway of apoptosis than 7BIO. The apoptotic
nature of cell death was also confirmed morphologically with the
DAPI staining method which revealed that both 6BIO and 7BIO -trea-
ted cells exhibit extensive condensed nuclear morphology (Fig 3E).
3.3. Effects of 6-BIO and 7-BIO on key proteins involved in apoptosis
and cell cycle regulation
To elucidate the downstream signaling pathways activated dur-
ing 6BIO and 7BIO -induced cell death, we evaluated the levels of
key proteins known to participate in the apoptotic pathways.
Immunoblotting analysis was performed at 0 (control), 6, 12, 24
36 and 48 h post-treatment with the antibodies indicated in
Fig. 4. Treatment with 6BIO resulted in an increase in the cleavage
of executioner caspase-3 that was associated with an enhanced
proteolytic processing of caspase-9 and consistent cleavage of Poly

























le regulation. MDA-MB-231-TXSA cells were treated with (A) 15 lM of 6BIO or (B)
ere used in Western blotting as described in the see Section 2. Quantification of
ng the image analysis software Image Quant 5.2. Every point is the mean ± SE of two
Table 2
Effect of indirubin derivatives on cell cycle distribution.MDA-MB-231-TXSA cells were treated with 15 lM 6BIO (A) or 15 lM 7BIO (B) for several
time points. Distribution of cell cycle was monitored by flow cytometry. The data are expressed as the mean (±SE) of the results from three separate
experiments.
Hour
Phase 0 6 12 24
(A)
DNA Content (%)
Sub-G1 3.7 (±0.7) 5.7 (±7.7) 21.1 (±1.7) 25.0 (±1.0)
G0/G1 41.0 (±1.3) 43.0 (±2.1) 48.8 (±0.2) 53.6 (±0.6)
S 22.2 (±0.9) 21.0 (±0.3) 8.8 (±1.2) 9.0 (±1.9)
G2/M 31.8 (±0.7) 29.2 (±0.4) 19.2 (±1.8) 11.1 (±0.6)
(B)
DNA Content (%)
Sub-G1 1.9 (±1.4) 2.5 (±0.4) 5.5 (±0.7) 39.4 (±2.4)
G0/G1 46.8 (±2.0) 38.3 (±1.7) 28.6 (±1.3) 34.6 (±1.4)
S 12.0 (±0.1) 9.6 (±1.3) 10.1 (±0.8) 7.5 (±1.9)
G2/M 38.6 (±0.7) 47.9 (±0.3) 54.4 (±0.9) 16.0 (±2.7)
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(Fig. 4A). On the other hand, treatment with 7BIO resulted in a time-
dependent increase in cleaved caspase-8 and an increase in the unc-
leaved levels of caspase-3 and caspase-9, with no associated cleav-
age. Furthermore, 7BIO increased the levels of FADD and Bax, PARP,
p53 and p21 and the total protein levels of the death receptors DR4
and DR5 were elevated in a time dependent manner (Fig. 4B and
D).The death receptors DR4 and DR5 associate through their func-
tional cytoplasmic death domain motifs with FAS-associated death
domain protein (FADD) upon activation by apoptotic signals
(extrinsic death receptor pathway). Since FADD is known to be in-
volved in the activation of caspase-8 [15], the increased surface
expression of DR4 and DR5 observed in 7BIO-treated MDA-MB-
231-TXSA cells is likely to contribute to the observed caspase-8
activation. DR4 and DR5 expression have been reported to be trans-
criptionally regulated by p53 [16,17]. Since the MDA-MB-231-TXSA
cell line (derived from MDA-MB-231cells) has a mutant p53 [18],
we can presume that the 7BIO-induced up-regulation of p21 is
through a p53 independent mechanism. Several studies have re-
ported increased p21 expression [19–21] or increased p21 protein
stability [22,23] via p53 independent signaling pathways.
Finally, we determined the effects of 6BIO and 7BIO on cell cycle
distribution (Table 2). 6BIO produced a time dependent increase in
G0/G1 DNA content. This was accompanied by a decrease in the G2/
M phase. A time dependent increase of sub-G1 phase was observed
which is indicative of apoptosis. Interestingly, the accumulation of
MDA-MB-231-TXSA cells in G0/G1 phase of the cell cycle after 6BIO
treatment seems to be independent of p21 (Fig. 4A). In contrast,
7BIO produced a time dependent decrease in G0/G1 DNA content.
This was accompanied by an initial increase in the G2/M phase
(0–12 h). An accumulation in G2/M phase of the cell cycle and
reduction of G0/G1 phase after 7BIO treatment is consistent with
the observed increase in p21 levels. p21 inhibits the activity of
the cyclin B1/Cdc2 complex [24], while GADD45 binds Cdc2 and
disrupts its ability to complex with cyclin B. Therefore, the in-
creased p21 protein levels in MDA-MB-231-TXSA cells treated with
7BIO strongly suggests that 7BIO induces cell cycle arrest at G2/M
phase. G2/M block is initiated as early as 6 h post treatment
whereas apoptosis is observed at 24 h post treatment (Table 2B).
In previous studies 7BIO has been characterized as an effective
cell killer acting in an apoptosis independent manner inducing ne-
crotic cell death in the human neuroblastoma cell line SH-SY5Y
and the T cell leukemia cell line Jurkat [8,11]. The death in these
cell lines by has been reported to be independent of p53 [8]. Fur-
thermore, IMR-5, IMR-32, Jurkat and HL-60 cells treated with
7BIO did not activate caspases and no apoptotic features were evi-
dent [8,9]. We investigated this possibility in our cell line using the‘‘necrotic assay’’ of Cell Death Detection ELISA Plus kit. We found
no evidence of necrotic cell death after treatment for up to 48 h
with 15 lM 7BIO (data not shown).
The results presented here show conclusively that in MDA-MB-
231-TXSA cells 7BIO induces clearly apoptotic cell death. This was
shown with five different methods (shown in Fig. 3 and Table 2):
DAPI staining (showing the characteristic morphology of apoptotic
nuclear fragmentation), the ELISA assay (detecting nucleosomes),
Annexin-V staining (detecting early apoptotic cells), caspase-3
activity assay and flow cytometry (detecting the number of cells
in present in sub-G1 phase of the cell cycle). However, the response
of different cancer cell lines to 7BIO through apoptotic or non-
apoptotic mechanisms seems to be a function of cell content. To
this end we have found that the PC3 and DU-145 prostate cancer
cells respond through non-apoptotic mechanisms to 7BIO (data
not shown).
In summary, this study elucidates for the first time, the distinct
molecular mechanisms underlying the apoptotic effects of 6BIO
and 7BIO on a highly invasive breast cancer cell line. Based on
the presented results it has been clearly established that in MDA-
MB-231-TXSA cells 6BIO activates the intrinsic caspase-9 and cas-
pase-3 mediated apoptotic pathway. In contrast, 7BIO activates
both the caspase-8 extrinsic pathway (which is associated with
the upregulation of DR4/DR5) and a caspase-independent pathway
of apoptosis. The employment of different molecular modes of
anti-tumor activity by two very closely related indirubin deriva-
tives could serve as a valuable tool in combination with chemo-
therapy protocols for the treatment of highly metastatic breast
cancer.
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